Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Colorectal Neoplasms 4Polycythemia Vera 3Myeloproliferative Disorders 3Stomach Neoplasms 2Cardiovascular Diseases 2Multiple Myeloma 1Hemorrhage 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Barrett Esophagus 1Adenomatous Polyps 1Adenoma 1

Interventions

ruxolitinib 16Hydroxyurea 7givinostat hydrochloride 5givinostat 5Phlebotomy 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2spartalizumab 1sonidegib 1sabatolimab 1pomalidomide 1pelcitoclax 1peginterferon alfa-2b 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1navitoclax 1lestaurtinib 1itacitinib 1imetelstat 1anagrelide 1RG7388 1Pipobroman 1Panobinostat 1ON 01910 1NIS-793 1Lenalidomide 1INCB039110 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Polycythemia Vera × Aspirin × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting
70 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

PharmaEssentia Japan K.K.

Phase 3 Completed
21 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡